{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T09:23:24Z","timestamp":1768641804561,"version":"3.49.0"},"reference-count":94,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2021,10,27]],"date-time":"2021-10-27T00:00:00Z","timestamp":1635292800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2021,10,27]],"date-time":"2021-10-27T00:00:00Z","timestamp":1635292800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["2000095"],"award-info":[{"award-number":["2000095"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Semin Immunopathol"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1007\/s00281-021-00895-4","type":"journal-article","created":{"date-parts":[[2021,10,27]],"date-time":"2021-10-27T14:02:58Z","timestamp":1635343378000},"page":"817-828","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["The emerging role of complement in neuromuscular disorders"],"prefix":"10.1007","volume":"43","author":[{"given":"John D.","family":"Lee","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Trent M.","family":"Woodruff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,10,27]]},"reference":[{"issue":"12","key":"895_CR1","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1038\/nri3761","volume":"14","author":"M Kolev","year":"2014","unstructured":"Kolev M, Le Friec G, Kemper C (2014) Complement\u2013tapping into new sites and effector systems. Nat Rev Immunol 14(12):811\u2013820","journal-title":"Nat Rev Immunol"},{"issue":"2","key":"895_CR2","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.immuni.2016.08.003","volume":"45","author":"C Hess","year":"2016","unstructured":"Hess C, Kemper C (2016) Complement-mediated regulation of metabolism and basic cellular processes. Immunity 45(2):240\u2013254","journal-title":"Immunity"},{"issue":"1","key":"895_CR3","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1007\/BF01181747","volume":"10","author":"J Desaki","year":"1981","unstructured":"Desaki J, Uehara Y (1981) The overall morphology of neuromuscular junctions as revealed by scanning electron microscopy. J Neurocytol 10(1):101\u2013110","journal-title":"J Neurocytol"},{"issue":"15","key":"895_CR4","doi-asserted-by":"publisher","first-page":"12601","DOI":"10.1074\/jbc.R200027200","volume":"278","author":"JR Sanes","year":"2003","unstructured":"Sanes JR (2003) The basement membrane\/basal lamina of skeletal muscle. J Biol Chem 278(15):12601\u201312604","journal-title":"J Biol Chem"},{"issue":"1","key":"895_CR5","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1083\/jcb.6.1.7","volume":"6","author":"E De Harven","year":"1959","unstructured":"De Harven E, Coers C (1959) Electron microscope study of the human neuromuscular junction. J Biophys Biochem Cytol 6(1):7\u201310","journal-title":"J Biophys Biochem Cytol"},{"issue":"5","key":"895_CR6","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/S1474-4422(15)00010-1","volume":"14","author":"AG Engel","year":"2015","unstructured":"Engel AG, Shen XM, Selcen D, Sine SM (2015) Congenital myasthenic syndromes: pathogenesis, diagnosis, and treatment. Lancet Neurol 14(5):461","journal-title":"Lancet Neurol"},{"issue":"1","key":"895_CR7","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/j.mcn.2010.09.010","volume":"46","author":"V Bernard","year":"2011","unstructured":"Bernard V, Girard E, Hrabovska A, Camp S, Taylor P, Plaud B, Krejci E (2011) Distinct localization of collagen Q and PRiMA forms of acetylcholinesterase at the neuromuscular junction. Mol Cell Neurosci 46(1):272\u2013281","journal-title":"Mol Cell Neurosci"},{"issue":"16","key":"895_CR8","doi-asserted-by":"publisher","first-page":"9654","DOI":"10.1073\/pnas.95.16.9654","volume":"95","author":"K Ohno","year":"1998","unstructured":"Ohno K, Brengman J, Tsujino A, Engel AG (1998) Human endplate acetylcholinesterase deficiency caused by mutations in the collagen-like tail subunit (ColQ) of the asymmetric enzyme. Proc Natl Acad Sci U S A 95(16):9654\u20139659","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"42","key":"895_CR9","doi-asserted-by":"publisher","first-page":"13892","DOI":"10.1523\/JNEUROSCI.1733-14.2014","volume":"34","author":"A Barik","year":"2014","unstructured":"Barik A, Lu Y, Sathyamurthy A, Bowman A, Shen C, Li L, Xiong WC, Mei L (2014) LRP4 is critical for neuromuscular junction maintenance. J Neurosci 34(42):13892\u201313905","journal-title":"J Neurosci"},{"issue":"1","key":"895_CR10","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/S0166-2236(97)01154-5","volume":"21","author":"MA Ruegg","year":"1998","unstructured":"Ruegg MA, Bixby JL (1998) Agrin orchestrates synaptic differentiation at the vertebrate neuromuscular junction. Trends Neurosci 21(1):22\u201327","journal-title":"Trends Neurosci"},{"issue":"2\u20133","key":"895_CR11","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.jaut.2007.02.001","volume":"28","author":"M Blank","year":"2007","unstructured":"Blank M, Shoenfeld Y (2007) B cell targeted therapy in autoimmunity. J Autoimmun 28(2\u20133):62\u201368","journal-title":"J Autoimmun"},{"issue":"6","key":"895_CR12","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1038\/s41590-021-00926-0","volume":"22","author":"A Cumpelik","year":"2021","unstructured":"Cumpelik A, Heja D, Hu Y, Varano G, Ordikhani F, Roberto MP, He Z, Homann D, Lira SA, Dominguez-Sola D, Heeger PS (2021) Dynamic regulation of B cell complement signaling is integral to germinal center responses. Nat Immunol 22(6):757\u2013768","journal-title":"Nat Immunol"},{"issue":"11","key":"895_CR13","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1038\/s41582-020-0400-0","volume":"16","author":"MC Dalakas","year":"2020","unstructured":"Dalakas MC, Alexopoulos H, Spaeth PJ (2020) Complement in neurological disorders and emerging complement-targeted therapeutics. Nat Rev Neurol 16(11):601\u2013617","journal-title":"Nat Rev Neurol"},{"key":"895_CR14","doi-asserted-by":"publisher","first-page":"342931","DOI":"10.1155\/2013\/342931","volume":"2013","author":"A Shastri","year":"2013","unstructured":"Shastri A, Bonifati DM, Kishore U (2013) Innate immunity and neuroinflammation. Mediators Inflamm 2013:342931","journal-title":"Mediators Inflamm"},{"issue":"9","key":"895_CR15","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1038\/ni.1923","volume":"11","author":"D Ricklin","year":"2010","unstructured":"Ricklin D, Hajishengallis G, Yang K, Lambris JD (2010) Complement: a key system for immune surveillance and homeostasis. Nat Immunol 11(9):785\u2013797","journal-title":"Nat Immunol"},{"issue":"7","key":"895_CR16","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1038\/nrneph.2016.70","volume":"12","author":"D Ricklin","year":"2016","unstructured":"Ricklin D, Reis ES, Lambris JD (2016) Complement in disease: a defence system turning offensive. Nat Rev Nephrol 12(7):383\u2013401","journal-title":"Nat Rev Nephrol"},{"issue":"2","key":"895_CR17","doi-asserted-by":"publisher","first-page":"630","DOI":"10.4049\/jimmunol.117.2.630","volume":"117","author":"MR Daha","year":"1976","unstructured":"Daha MR, Fearon DT, Austen KF (1976) C3 requirements for formation of alternative pathway C5 convertase. J Immunol 117(2):630\u2013634","journal-title":"J Immunol"},{"issue":"11","key":"895_CR18","doi-asserted-by":"publisher","first-page":"2114","DOI":"10.1016\/j.biocel.2009.04.005","volume":"41","author":"HD Manthey","year":"2009","unstructured":"Manthey HD, Woodruff TM, Taylor SM, Monk PN (2009) Complement component 5a (C5a). Int J Biochem Cell Biol 41(11):2114\u20132117","journal-title":"Int J Biochem Cell Biol"},{"issue":"3","key":"895_CR19","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.celrep.2012.02.003","volume":"1","author":"MA Hadders","year":"2012","unstructured":"Hadders MA, Bubeck D, Roversi P, Hakobyan S, Forneris F, Morgan BP, Pangburn MK, Llorca O, Lea SM, Gros P (2012) Assembly and regulation of the membrane attack complex based on structures of C5b6 and sC5b9. Cell Rep 1(3):200\u2013207","journal-title":"Cell Rep"},{"issue":"10","key":"895_CR20","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1038\/nri2620","volume":"9","author":"PF Zipfel","year":"2009","unstructured":"Zipfel PF, Skerka C (2009) Complement regulators and inhibitory proteins. Nat Rev Immunol 9(10):729\u2013740","journal-title":"Nat Rev Immunol"},{"issue":"2","key":"895_CR21","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1074\/jbc.M109322200","volume":"277","author":"DE Hourcade","year":"2002","unstructured":"Hourcade DE, Mitchell L, Kuttner-Kondo LA, Atkinson JP, Medof ME (2002) Decay-accelerating factor (DAF), complement receptor 1 (CR1), and factor H dissociate the complement AP C3 convertase (C3bBb) via sites on the type A domain of Bb. J Biol Chem 277(2):1107\u20131112","journal-title":"J Biol Chem"},{"issue":"1","key":"895_CR22","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1002\/(SICI)1097-4598(199701)20:1<92::AID-MUS12>3.0.CO;2-3","volume":"20","author":"JM Navenot","year":"1997","unstructured":"Navenot JM, Villanova M, Lucas-Heron B, Malandrini A, Blanchard D, Louboutin JP (1997) Expression of CD59, a regulator of the membrane attack complex of complement, on human skeletal muscle fibers. Muscle Nerve 20(1):92\u201396","journal-title":"Muscle Nerve"},{"issue":"5","key":"895_CR23","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1038\/nrneurol.2016.44","volume":"12","author":"NE Gilhus","year":"2016","unstructured":"Gilhus NE, Skeie GO, Romi F, Lazaridis K, Zisimopoulou P, Tzartos S (2016) Myasthenia gravis - autoantibody characteristics and their implications for therapy. Nat Rev Neurol 12(5):259\u2013268","journal-title":"Nat Rev Neurol"},{"issue":"1","key":"895_CR24","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/s41572-019-0079-y","volume":"5","author":"NE Gilhus","year":"2019","unstructured":"Gilhus NE, Tzartos S, Evoli A, Palace J, Burns TM, Verschuuren J (2019) Myasthenia gravis. Nat Rev Dis Primers 5(1):30","journal-title":"Nat Rev Dis Primers"},{"issue":"1","key":"895_CR25","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1111\/nyas.13592","volume":"1413","author":"A Vincent","year":"2018","unstructured":"Vincent A, Huda S, Cao M, Cetin H, Koneczny I, Rodriguez Cruz PM, Jacobson L, Viegas S, Jacob S, Woodhall M, Nagaishi A, Maniaol A, Damato V, Leite MI, Cossins J, Webster R, Palace J, Beeson D (2018) Serological and experimental studies in different forms of myasthenia gravis. Ann N Y Acad Sci 1413(1):143\u2013153","journal-title":"Ann N Y Acad Sci"},{"issue":"12","key":"895_CR26","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1016\/S1474-4422(17)30363-0","volume":"16","author":"NE Gilhus","year":"2017","unstructured":"Gilhus NE (2017) Eculizumab: a treatment option for myasthenia gravis? Lancet Neurol 16(12):947\u2013948","journal-title":"Lancet Neurol"},{"issue":"9","key":"895_CR27","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1016\/j.autrev.2013.03.003","volume":"12","author":"E Tuzun","year":"2013","unstructured":"Tuzun E, Christadoss P (2013) Complement associated pathogenic mechanisms in myasthenia gravis. Autoimmun Rev 12(9):904\u2013911","journal-title":"Autoimmun Rev"},{"issue":"7","key":"895_CR28","doi-asserted-by":"publisher","first-page":"3847","DOI":"10.4049\/jimmunol.171.7.3847","volume":"171","author":"E Tuzun","year":"2003","unstructured":"Tuzun E, Scott BG, Goluszko E, Higgs S, Christadoss P (2003) Genetic evidence for involvement of classical complement pathway in induction of experimental autoimmune myasthenia gravis. J Immunol 171(7):3847\u20133854","journal-title":"J Immunol"},{"issue":"11","key":"895_CR29","doi-asserted-by":"publisher","first-page":"2843","DOI":"10.1172\/JCI29894","volume":"116","author":"BM Conti-Fine","year":"2006","unstructured":"Conti-Fine BM, Milani M, Kaminski HJ (2006) Myasthenia gravis: past, present, and future. J Clin Invest 116(11):2843\u20132854","journal-title":"J Clin Invest"},{"key":"895_CR30","doi-asserted-by":"publisher","first-page":"177","DOI":"10.3181\/00379727-105-26050","volume":"105","author":"WL Nastuk","year":"1960","unstructured":"Nastuk WL, Plescia OJ, Osserman KE (1960) Changes in serum complement activity in patients with myasthenia gravis. Proc Soc Exp Biol Med 105:177\u2013184","journal-title":"Proc Soc Exp Biol Med"},{"issue":"2","key":"895_CR31","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1111\/j.1749-6632.1965.tb18999.x","volume":"124","author":"AJ Strauss","year":"1965","unstructured":"Strauss AJ, van der Geld HW, Kemp PG Jr, Exum ED, Goodman HC (1965) Immunological concomitants of myasthenia gravis. Ann N Y Acad Sci 124(2):744\u2013766","journal-title":"Ann N Y Acad Sci"},{"issue":"4","key":"895_CR32","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/0303-8467(93)90103-N","volume":"95","author":"RJ Barohn","year":"1993","unstructured":"Barohn RJ, Brey RL (1993) Soluble terminal complement components in human myasthenia gravis. Clin Neurol Neurosurg 95(4):285\u2013290","journal-title":"Clin Neurol Neurosurg"},{"issue":"1\u20132","key":"895_CR33","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.jneuroim.2004.08.002","volume":"158","author":"F Romi","year":"2005","unstructured":"Romi F, Kristoffersen EK, Aarli JA, Gilhus NE (2005) The role of complement in myasthenia gravis: serological evidence of complement consumption in vivo. J Neuroimmunol 158(1\u20132):191\u2013194","journal-title":"J Neuroimmunol"},{"issue":"5","key":"895_CR34","first-page":"267","volume":"52","author":"AG Engel","year":"1977","unstructured":"Engel AG, Lambert EH, Howard FM (1977) Immune complexes (IgG and C3) at the motor end-plate in myasthenia gravis: ultrastructural and light microscopic localization and electrophysiologic correlations. Mayo Clin Proc 52(5):267\u2013280","journal-title":"Mayo Clin Proc"},{"key":"895_CR35","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1111\/j.1749-6632.1981.tb33730.x","volume":"377","author":"AG Engel","year":"1981","unstructured":"Engel AG, Sahashi K, Fumagalli G (1981) The immunopathology of acquired myasthenia gravis. Ann N Y Acad Sci 377:158\u2013174","journal-title":"Ann N Y Acad Sci"},{"issue":"6","key":"895_CR36","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1212\/WNL.43.6.1167","volume":"43","author":"S Nakano","year":"1993","unstructured":"Nakano S, Engel AG (1993) Myasthenia gravis: quantitative immunocytochemical analysis of inflammatory cells and detection of complement membrane attack complex at the end-plate in 30 patients. Neurology 43(6):1167\u20131172","journal-title":"Neurology"},{"issue":"12","key":"895_CR37","doi-asserted-by":"publisher","first-page":"4584","DOI":"10.1073\/pnas.73.12.4584","volume":"73","author":"JE Rash","year":"1976","unstructured":"Rash JE, Albuquerque EX, Hudson CS, Mayer RF, Satterfield JR (1976) Studies of human myasthenia gravis: electrophysiological and ultrastructural evidence compatible with antibody attachment to acetylcholine receptor complex. Proc Natl Acad Sci U S A 73(12):4584\u20134588","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"895_CR38","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1097\/00005072-198003000-00005","volume":"39","author":"K Sahashi","year":"1980","unstructured":"Sahashi K, Engel AG, Lambert EH, Howard FM Jr (1980) Ultrastructural localization of the terminal and lytic ninth complement component (C9) at the motor end-plate in myasthenia gravis. J Neuropathol Exp Neurol 39(2):160\u2013172","journal-title":"J Neuropathol Exp Neurol"},{"issue":"12","key":"895_CR39","doi-asserted-by":"publisher","first-page":"1748","DOI":"10.1212\/WNL.35.12.1748","volume":"35","author":"T Ashizawa","year":"1985","unstructured":"Ashizawa T, Appel SH (1985) Complement-dependent lysis of cultured rat myotubes by myasthenic immunoglobulins. Neurology 35(12):1748\u20131753","journal-title":"Neurology"},{"issue":"1","key":"895_CR40","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1111\/ene.14500","volume":"28","author":"Y Ozawa","year":"2021","unstructured":"Ozawa Y, Uzawa A, Yasuda M, Kojima Y, Oda F, Himuro K, Kawaguchi N, Kuwabara S (2021) Changes in serum complements and their regulators in generalized myasthenia gravis. Eur J Neurol 28(1):314\u2013322","journal-title":"Eur J Neurol"},{"issue":"1","key":"895_CR41","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s00005-011-0158-6","volume":"60","author":"F Baggi","year":"2012","unstructured":"Baggi F, Antozzi C, Toscani C, Cordiglieri C (2012) Acetylcholine receptor-induced experimental myasthenia gravis: what have we learned from animal models after three decades? Arch Immunol Ther Exp (Warsz) 60(1):19\u201330","journal-title":"Arch Immunol Ther Exp (Warsz)"},{"issue":"4","key":"895_CR42","doi-asserted-by":"publisher","first-page":"2697","DOI":"10.4049\/jimmunol.172.4.2697","volume":"172","author":"F Baggi","year":"2004","unstructured":"Baggi F, Annoni A, Ubiali F, Milani M, Longhi R, Scaioli W, Cornelio F, Mantegazza R, Antozzi C (2004) Breakdown of tolerance to a self-peptide of acetylcholine receptor alpha-subunit induces experimental myasthenia gravis in rats. J Immunol 172(4):2697\u20132703","journal-title":"J Immunol"},{"key":"895_CR43","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.expneurol.2015.03.010","volume":"270","author":"M Losen","year":"2015","unstructured":"Losen M, Martinez-Martinez P, Molenaar PC, Lazaridis K, Tzartos S, Brenner T, Duan RS, Luo J, Lindstrom J, Kusner L (2015) Standardization of the experimental autoimmune myasthenia gravis (EAMG) model by immunization of rats with Torpedo californica acetylcholine receptors\u2013Recommendations for methods and experimental designs. Exp Neurol 270:18\u201328","journal-title":"Exp Neurol"},{"key":"895_CR44","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.expneurol.2015.02.009","volume":"270","author":"E Tuzun","year":"2015","unstructured":"Tuzun E, Berrih-Aknin S, Brenner T, Kusner LL, Le Panse R, Yang H, Tzartos S, Christadoss P (2015) Guidelines for standard preclinical experiments in the mouse model of myasthenia gravis induced by acetylcholine receptor immunization. Exp Neurol 270:11\u201317","journal-title":"Exp Neurol"},{"issue":"2","key":"895_CR45","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1006\/clim.1999.4807","volume":"94","author":"P Christadoss","year":"2000","unstructured":"Christadoss P, Poussin M, Deng C (2000) Animal models of myasthenia gravis. Clin Immunol 94(2):75\u201387","journal-title":"Clin Immunol"},{"issue":"2","key":"895_CR46","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1212\/WNL.29.2.179","volume":"29","author":"AG Engel","year":"1979","unstructured":"Engel AG, Sakakibara H, Sahashi K, Lindstrom JM, Lambert EH, Lennon VA (1979) Passively transferred experimental autoimmune myasthenia gravis. Sequential and quantitative study of the motor end-plate fine structure and ultrastructural localization of immune complexes (IgG and C3), and of the acetylcholine receptor. Neurology 29(2):179\u201388","journal-title":"Neurology"},{"issue":"2","key":"895_CR47","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1097\/00005072-197803000-00008","volume":"37","author":"K Sahashi","year":"1978","unstructured":"Sahashi K, Engel AG, Linstrom JM, Lambert EH, Lennon VA (1978) Ultrastructural localization of immune complexes (IgG and C3) at the end-plate in experimental autoimmune myasthenia gravis. J Neuropathol Exp Neurol 37(2):212\u2013223","journal-title":"J Neuropathol Exp Neurol"},{"issue":"1\u20132","key":"895_CR48","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.jneuroim.2008.12.013","volume":"208","author":"J Li","year":"2009","unstructured":"Li J, Qi H, Tuzun E, Allman W, Yilmaz V, Saini SS, Deymeer F, Saruhan-Direskeneli G, Christadoss P (2009) Mannose-binding lectin pathway is not involved in myasthenia gravis pathogenesis. J Neuroimmunol 208(1\u20132):40\u201345","journal-title":"J Neuroimmunol"},{"key":"895_CR49","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.jaut.2013.01.003","volume":"42","author":"R Huda","year":"2013","unstructured":"Huda R, Tuzun E, Christadoss P (2013) Complement C2 siRNA mediated therapy of myasthenia gravis in mice. J Autoimmun 42:94\u2013104","journal-title":"J Autoimmun"},{"issue":"1\u20132","key":"895_CR50","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.jneuroim.2006.10.014","volume":"182","author":"E Tuzun","year":"2007","unstructured":"Tuzun E, Li J, Saini SS, Yang H, Christadoss P (2007) Pros and cons of treating murine myasthenia gravis with anti-C1q antibody. J Neuroimmunol 182(1\u20132):167\u2013176","journal-title":"J Neuroimmunol"},{"issue":"2","key":"895_CR51","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1111\/j.1365-2249.2006.03198.x","volume":"146","author":"J Chamberlain-Banoub","year":"2006","unstructured":"Chamberlain-Banoub J, Neal JW, Mizuno M, Harris CL, Morgan BP (2006) Complement membrane attack is required for endplate damage and clinical disease in passive experimental myasthenia gravis in Lewis rats. Clin Exp Immunol 146(2):278\u2013286","journal-title":"Clin Exp Immunol"},{"issue":"8","key":"895_CR52","doi-asserted-by":"publisher","first-page":"2589","DOI":"10.4049\/jimmunol.140.8.2589","volume":"140","author":"P Christadoss","year":"1988","unstructured":"Christadoss P (1988) C5 gene influences the development of murine myasthenia gravis. J Immunol 140(8):2589\u20132592","journal-title":"J Immunol"},{"issue":"1\u20132","key":"895_CR53","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.jneuroim.2008.03.007","volume":"196","author":"H Qi","year":"2008","unstructured":"Qi H, Tuzun E, Allman W, Saini SS, Penabad ZR, Pierangeli S, Christadoss P (2008) C5a is not involved in experimental autoimmune myasthenia gravis pathogenesis. J Neuroimmunol 196(1\u20132):101\u2013106","journal-title":"J Neuroimmunol"},{"issue":"8","key":"895_CR54","doi-asserted-by":"publisher","first-page":"2654","DOI":"10.4049\/jimmunol.142.8.2654","volume":"142","author":"G Biesecker","year":"1989","unstructured":"Biesecker G, Gomez CM (1989) Inhibition of acute passive transfer experimental autoimmune myasthenia gravis with Fab antibody to complement C6. J Immunol 142(8):2654\u20132659","journal-title":"J Immunol"},{"issue":"1","key":"895_CR55","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1002\/ana.21536","volume":"65","author":"J Soltys","year":"2009","unstructured":"Soltys J, Kusner LL, Young A, Richmonds C, Hatala D, Gong B, Shanmugavel V, Kaminski HJ (2009) Novel complement inhibitor limits severity of experimentally myasthenia gravis. Ann Neurol 65(1):67\u201375","journal-title":"Ann Neurol"},{"issue":"12","key":"895_CR56","doi-asserted-by":"publisher","first-page":"8562","DOI":"10.4049\/jimmunol.179.12.8562","volume":"179","author":"Y Zhou","year":"2007","unstructured":"Zhou Y, Gong B, Lin F, Rother RP, Medof ME, Kaminski HJ (2007) Anti-C5 antibody treatment ameliorates weakness in experimentally acquired myasthenia gravis. J Immunol 179(12):8562\u20138567","journal-title":"J Immunol"},{"issue":"2","key":"895_CR57","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.expneurol.2006.06.003","volume":"202","author":"HJ Kaminski","year":"2006","unstructured":"Kaminski HJ, Kusner LL, Richmonds C, Medof ME, Lin F (2006) Deficiency of decay accelerating factor and CD59 leads to crisis in experimental myasthenia. Exp Neurol 202(2):287\u2013293","journal-title":"Exp Neurol"},{"issue":"9","key":"895_CR58","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1172\/JCI0216086","volume":"110","author":"F Lin","year":"2002","unstructured":"Lin F, Kaminski HJ, Conti-Fine BM, Wang W, Richmonds C, Medof ME (2002) Markedly enhanced susceptibility to experimental autoimmune myasthenia gravis in the absence of decay-accelerating factor protection. J Clin Invest 110(9):1269\u20131274","journal-title":"J Clin Invest"},{"issue":"2","key":"895_CR59","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1111\/j.1365-2249.2006.03205.x","volume":"146","author":"BP Morgan","year":"2006","unstructured":"Morgan BP, Chamberlain-Banoub J, Neal JW, Song W, Mizuno M, Harris CL (2006) The membrane attack pathway of complement drives pathology in passively induced experimental autoimmune myasthenia gravis in mice. Clin Exp Immunol 146(2):294\u2013302","journal-title":"Clin Exp Immunol"},{"issue":"1\u20132","key":"895_CR60","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.jneuroim.2006.07.016","volume":"181","author":"E Tuzun","year":"2006","unstructured":"Tuzun E, Saini SS, Morgan BP, Christadoss P (2006) Complement regulator CD59 deficiency fails to augment susceptibility to actively induced experimental autoimmune myasthenia gravis. J Neuroimmunol 181(1\u20132):29\u201333","journal-title":"J Neuroimmunol"},{"issue":"1\u20132","key":"895_CR61","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/S0165-5728(96)00144-0","volume":"71","author":"SJ Piddlesden","year":"1996","unstructured":"Piddlesden SJ, Jiang S, Levin JL, Vincent A, Morgan BP (1996) Soluble complement receptor 1 (sCR1) protects against experimental autoimmune myasthenia gravis. J Neuroimmunol 71(1\u20132):173\u2013177","journal-title":"J Neuroimmunol"},{"issue":"2","key":"895_CR62","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.molimm.2007.06.144","volume":"45","author":"NJ Hepburn","year":"2008","unstructured":"Hepburn NJ, Chamberlain-Banoub JL, Williams AS, Morgan BP, Harris CL (2008) Prevention of experimental autoimmune myasthenia gravis by rat Crry-Ig: a model agent for long-term complement inhibition in vivo. Mol Immunol 45(2):395\u2013405","journal-title":"Mol Immunol"},{"issue":"5","key":"895_CR63","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1002\/mus.24057","volume":"49","author":"LL Kusner","year":"2014","unstructured":"Kusner LL, Satija N, Cheng G, Kaminski HJ (2014) Targeting therapy to the neuromuscular junction: proof of concept. Muscle Nerve 49(5):749\u2013756","journal-title":"Muscle Nerve"},{"issue":"10","key":"895_CR64","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1016\/S1474-4422(15)00145-3","volume":"14","author":"NE Gilhus","year":"2015","unstructured":"Gilhus NE, Verschuuren JJ (2015) Myasthenia gravis: subgroup classification and therapeutic strategies. Lancet Neurol 14(10):1023\u20131036","journal-title":"Lancet Neurol"},{"key":"895_CR65","doi-asserted-by":"publisher","first-page":"151","DOI":"10.2147\/NDT.S8915","volume":"7","author":"R Mantegazza","year":"2011","unstructured":"Mantegazza R, Bonanno S, Camera G, Antozzi C (2011) Current and emerging therapies for the treatment of myasthenia gravis. Neuropsychiatr Dis Treat 7:151\u2013160","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"4","key":"895_CR66","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1097\/CND.0000000000000034","volume":"15","author":"NJ Silvestri","year":"2014","unstructured":"Silvestri NJ, Wolfe GI (2014) Treatment-refractory myasthenia gravis. J Clin Neuromuscul Dis 15(4):167\u2013178","journal-title":"J Clin Neuromuscul Dis"},{"issue":"2","key":"895_CR67","first-page":"255","volume":"86","author":"J Suh","year":"2013","unstructured":"Suh J, Goldstein JM, Nowak RJ (2013) Clinical characteristics of refractory myasthenia gravis patients. Yale J Biol Med 86(2):255\u2013260","journal-title":"Yale J Biol Med"},{"issue":"23","key":"895_CR68","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1056\/NEJMoa1208981","volume":"368","author":"CM Legendre","year":"2013","unstructured":"Legendre CM, Licht C, Muus P, Greenbaum LA, Babu S, Bedrosian C, Bingham C, Cohen DJ, Delmas Y, Douglas K, Eitner F, Feldkamp T, Fouque D, Furman RR, Gaber O, Herthelius M, Hourmant M, Karpman D, Lebranchu Y, Mariat C, Menne J, Moulin B, Nurnberger J, Ogawa M, Remuzzi G, Richard T, Sberro-Soussan R, Severino B, Sheerin NS, Trivelli A, Zimmerhackl LB, Goodship T, Loirat C (2013) Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med 368(23):2169\u20132181","journal-title":"N Engl J Med"},{"issue":"1","key":"895_CR69","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1002\/mus.23839","volume":"48","author":"J.F. Howard, Jr., R.J. Barohn, G.R. Cutter, M. Freimer, V.C. Juel, T. Mozaffar, M.L. Mellion, M.G. Benatar, M.E. Farrugia, J.J. Wang, S.S. Malhotra, J.T. Kissel, M.G.S. Group","year":"2013","unstructured":"J.F. Howard, Jr., R.J. Barohn, G.R. Cutter, M. Freimer, V.C. Juel, T. Mozaffar, M.L. Mellion, M.G. Benatar, M.E. Farrugia, J.J. Wang, S.S. Malhotra, J.T. Kissel, M.G.S. Group (2013) A randomized, double-blind, placebo-controlled phase II study of eculizumab in patients with refractory generalized myasthenia gravis. Muscle Nerve 48(1):76\u201384","journal-title":"Muscle Nerve"},{"issue":"12","key":"895_CR70","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1016\/S1474-4422(17)30369-1","volume":"16","author":"J.F. Howard, Jr., K. Utsugisawa, M. Benatar, H. Murai, R.J. Barohn, I. Illa, S. Jacob, J. Vissing, T.M. Burns, J.T. Kissel, S. Muppidi, R.J. Nowak, F. O\u2019Brien, J.J. Wang, R. Mantegazza, R.S. Group","year":"2017","unstructured":"J.F. Howard, Jr., K. Utsugisawa, M. Benatar, H. Murai, R.J. Barohn, I. Illa, S. Jacob, J. Vissing, T.M. Burns, J.T. Kissel, S. Muppidi, R.J. Nowak, F. O\u2019Brien, J.J. Wang, R. Mantegazza, R.S. Group (2017) Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study. Lancet Neurol 16(12):976\u2013986","journal-title":"Lancet Neurol"},{"issue":"1","key":"895_CR71","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1002\/mus.26447","volume":"60","author":"S Muppidi","year":"2019","unstructured":"Muppidi S, Utsugisawa K, Benatar M, Murai H, Barohn RJ, Illa I, Jacob S, Vissing J, Burns TM, Kissel JT, Nowak RJ, Andersen H, Casasnovas C, de Bleecker JL, Vu TH, Mantegazza R, O\u2019Brien FL, Wang JJ, Fujita KP, Howard JF Jr, G. Regain Study (2019) Long-term safety and efficacy of eculizumab in generalized myasthenia gravis. Muscle Nerve 60(1):14\u201324","journal-title":"Muscle Nerve"},{"issue":"3","key":"895_CR72","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1007\/s40265-018-0875-9","volume":"78","author":"S Dhillon","year":"2018","unstructured":"Dhillon S (2018) Eculizumab: a review in generalized myasthenia gravis. Drugs 78(3):367\u2013376","journal-title":"Drugs"},{"issue":"7","key":"895_CR73","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1056\/NEJMoa1311084","volume":"370","author":"J Nishimura","year":"2014","unstructured":"Nishimura J, Yamamoto M, Hayashi S, Ohyashiki K, Ando K, Brodsky AL, Noji H, Kitamura K, Eto T, Takahashi T, Masuko M, Matsumoto T, Wano Y, Shichishima T, Shibayama H, Hase M, Li L, Johnson K, Lazarowski A, Tamburini P, Inazawa J, Kinoshita T, Kanakura Y (2014) Genetic variants in C5 and poor response to eculizumab. N Engl J Med 370(7):632\u2013639","journal-title":"N Engl J Med"},{"key":"895_CR74","doi-asserted-by":"publisher","first-page":"17085","DOI":"10.1038\/nrdp.2017.85","volume":"3","author":"O Hardiman","year":"2017","unstructured":"Hardiman O, Al-Chalabi A, Chio A, Corr EM, Logroscino G, Robberecht W, Shaw PJ, Simmons Z, van den Berg LH (2017) Amyotrophic lateral sclerosis. Nat Rev Dis Primers 3:17085","journal-title":"Nat Rev Dis Primers"},{"issue":"16","key":"895_CR75","doi-asserted-by":"publisher","first-page":"1602","DOI":"10.1056\/NEJMc1710379","volume":"377","author":"RH Brown Jr","year":"2017","unstructured":"Brown RH Jr, Al-Chalabi A (2017) Amyotrophic lateral sclerosis. N Engl J Med 377(16):1602","journal-title":"N Engl J Med"},{"key":"895_CR76","doi-asserted-by":"publisher","first-page":"362","DOI":"10.3389\/fimmu.2019.00362","volume":"10","author":"SM Carpanini","year":"2019","unstructured":"Carpanini SM, Torvell M, Morgan BP (2019) Therapeutic inhibition of the complement system in diseases of the central nervous system. Front Immunol 10:362","journal-title":"Front Immunol"},{"key":"895_CR77","doi-asserted-by":"publisher","first-page":"101340","DOI":"10.1016\/j.smim.2019.101340","volume":"45","author":"JD Lee","year":"2019","unstructured":"Lee JD, Coulthard LG, Woodruff TM (2019) Complement dysregulation in the central nervous system during development and disease. Semin Immunol 45:101340","journal-title":"Semin Immunol"},{"key":"895_CR78","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.nbd.2019.03.003","volume":"127","author":"SE Parker","year":"2019","unstructured":"Parker SE, Hanton AM, Stefanou SN, Noakes PG, Woodruff TM, Lee JD (2019) Revisiting the role of the innate immune complement system in ALS. Neurobiol Dis 127:223\u2013232","journal-title":"Neurobiol Dis"},{"key":"895_CR79","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.molimm.2018.06.007","volume":"102","author":"AL Kjaeldgaard","year":"2018","unstructured":"Kjaeldgaard AL, Pilely K, Olsen KS, Pedersen SW, Lauritsen AO, Moller K, Garred P (2018) Amyotrophic lateral sclerosis: the complement and inflammatory hypothesis. Mol Immunol 102:14\u201325","journal-title":"Mol Immunol"},{"issue":"1\u20132","key":"895_CR80","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.jneuroim.2011.03.011","volume":"235","author":"B Heurich","year":"2011","unstructured":"Heurich B, El Idrissi NB, Donev RM, Petri S, Claus P, Neal J, Morgan BP, Ramaglia V (2011) Complement upregulation and activation on motor neurons and neuromuscular junction in the SOD1 G93A mouse model of familial amyotrophic lateral sclerosis. J Neuroimmunol 235(1\u20132):104\u2013109","journal-title":"J Neuroimmunol"},{"key":"895_CR81","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1186\/1742-2094-10-119","volume":"10","author":"JD Lee","year":"2013","unstructured":"Lee JD, Kamaruzaman NA, Fung JN, Taylor SM, Turner BJ, Atkin JD, Woodruff TM, Noakes PG (2013) Dysregulation of the complement cascade in the hSOD1G93A transgenic mouse model of amyotrophic lateral sclerosis. J Neuroinflammation 10:119","journal-title":"J Neuroinflammation"},{"issue":"8","key":"895_CR82","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1111\/bph.13730","volume":"174","author":"JD Lee","year":"2017","unstructured":"Lee JD, Kumar V, Fung JN, Ruitenberg MJ, Noakes PG, Woodruff TM (2017) Pharmacological inhibition of complement C5a\u2013C5a1 receptor signalling ameliorates disease pathology in the hSOD1(G93A) mouse model of amyotrophic lateral sclerosis. Br J Pharmacol 174(8):689\u2013699","journal-title":"Br J Pharmacol"},{"issue":"1\u20132","key":"895_CR83","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.jneuroim.2014.09.005","volume":"276","author":"S Mantovani","year":"2014","unstructured":"Mantovani S, Gordon R, Macmaw JK, Pfluger CM, Henderson RD, Noakes PG, McCombe PA, Woodruff TM (2014) Elevation of the terminal complement activation products C5a and C5b\u20139 in ALS patient blood. J Neuroimmunol 276(1\u20132):213\u2013218","journal-title":"J Neuroimmunol"},{"issue":"3","key":"895_CR84","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.nbd.2011.01.002","volume":"42","author":"M Sta","year":"2011","unstructured":"Sta M, Sylva-Steenland RM, Casula M, de Jong JM, Troost D, Aronica E, Baas F (2011) Innate and adaptive immunity in amyotrophic lateral sclerosis: evidence of complement activation. Neurobiol Dis 42(3):211\u2013220","journal-title":"Neurobiol Dis"},{"issue":"1","key":"895_CR85","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s13395-017-0128-8","volume":"7","author":"HA Wang","year":"2017","unstructured":"Wang HA, Lee JD, Lee KM, Woodruff TM, Noakes PG (2017) Complement C5a\u2013C5aR1 signalling drives skeletal muscle macrophage recruitment in the hSOD1(G93A) mouse model of amyotrophic lateral sclerosis. Skelet Muscle 7(1):10","journal-title":"Skelet Muscle"},{"issue":"1","key":"895_CR86","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s12974-016-0538-2","volume":"13","author":"N Bahia El Idrissi","year":"2016","unstructured":"Bahia El Idrissi N, Bosch S, Ramaglia V, Aronica E, Baas F, Troost D (2016) Complement activation at the motor end-plates in amyotrophic lateral sclerosis. J Neuroinflammation 13(1):72","journal-title":"J Neuroinflammation"},{"issue":"1","key":"895_CR87","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1186\/s12974-018-1217-2","volume":"15","author":"JD Lee","year":"2018","unstructured":"Lee JD, Levin SC, Willis EF, Li R, Woodruff TM, Noakes PG (2018) Complement components are upregulated and correlate with disease progression in the TDP-43(Q331K) mouse model of amyotrophic lateral sclerosis. J Neuroinflammation 15(1):171","journal-title":"J Neuroinflammation"},{"issue":"1","key":"895_CR88","doi-asserted-by":"publisher","first-page":"E3","DOI":"10.1073\/pnas.1321248111","volume":"111","author":"TM Woodruff","year":"2014","unstructured":"Woodruff TM, Lee JD, Noakes PG (2014) Role for terminal complement activation in amyotrophic lateral sclerosis disease progression. Proc Natl Acad Sci U S A 111(1):E3-4","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"10213","key":"895_CR89","doi-asserted-by":"publisher","first-page":"2025","DOI":"10.1016\/S0140-6736(19)32910-1","volume":"394","author":"E Mercuri","year":"2019","unstructured":"Mercuri E, Bonnemann CG, Muntoni F (2019) Muscular dystrophies. Lancet 394(10213):2025\u20132038","journal-title":"Lancet"},{"issue":"5","key":"895_CR90","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1016\/j.ajpath.2016.12.019","volume":"187","author":"J Hyzewicz","year":"2017","unstructured":"Hyzewicz J, Tanihata J, Kuraoka M, Nitahara-Kasahara Y, Beylier T, Ruegg UT, Vater A, Takeda S (2017) Low-intensity training and the C5a complement antagonist NOX-D21 rescue the mdx phenotype through modulation of inflammation. Am J Pathol 187(5):1147\u20131161","journal-title":"Am J Pathol"},{"issue":"3","key":"895_CR91","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1002\/ana.410120314","volume":"12","author":"AG Engel","year":"1982","unstructured":"Engel AG, Biesecker G (1982) Complement activation in muscle fiber necrosis: demonstration of the membrane attack complex of complement in necrotic fibers. Ann Neurol 12(3):289\u2013296","journal-title":"Ann Neurol"},{"issue":"299","key":"895_CR92","doi-asserted-by":"publisher","first-page":"299rv4","DOI":"10.1126\/scitranslmed.aaa7322","volume":"7","author":"AS Rosenberg","year":"2015","unstructured":"Rosenberg AS, Puig M, Nagaraju K, Hoffman EP, Villalta SA, Rao VA, Wakefield LM, Woodcock J (2015) Immune-mediated pathology in Duchenne muscular dystrophy. Sci Transl Med 7(299):299rv4","journal-title":"Sci Transl Med"},{"issue":"12","key":"895_CR93","doi-asserted-by":"publisher","first-page":"4366","DOI":"10.1172\/JCI42390","volume":"120","author":"R Han","year":"2010","unstructured":"Han R, Frett EM, Levy JR, Rader EP, Lueck JD, Bansal D, Moore SA, Ng R, Beltran-Valero de Bernabe D, Faulkner JA, Campbell KP (2010) Genetic ablation of complement C3 attenuates muscle pathology in dysferlin-deficient mice. J Clin Invest 120(12):4366\u20134374","journal-title":"J Clin Invest"},{"issue":"1","key":"895_CR94","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1111\/nyas.13522","volume":"1412","author":"JF Howard Jr","year":"2018","unstructured":"Howard JF Jr (2018) Myasthenia gravis: the role of complement at the neuromuscular junction. Ann N Y Acad Sci 1412(1):113\u2013128","journal-title":"Ann N Y Acad Sci"}],"container-title":["Seminars in Immunopathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00281-021-00895-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00281-021-00895-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00281-021-00895-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,11]],"date-time":"2023-11-11T20:35:32Z","timestamp":1699734932000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00281-021-00895-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,27]]},"references-count":94,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["895"],"URL":"https:\/\/doi.org\/10.1007\/s00281-021-00895-4","relation":{},"ISSN":["1863-2297","1863-2300"],"issn-type":[{"value":"1863-2297","type":"print"},{"value":"1863-2300","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,27]]},"assertion":[{"value":"17 August 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 September 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 October 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"TMW holds patents and patent applications relating to the use of complement inhibitors for neurological disease.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interest"}}]}}